Brought to you by 
Palau Pharma gives Affectis rights to Cox-2 inhibitor
24 Oct 2007
Executive Summary
In its first deal since a minority position in it was spun out last November, Grupo Uriach's R&D divison Palau Pharma SA (autoimmune and anti-inflammatory medicines) has licensed CNS disease firm Affectis Pharmaceuticals AG exclusive worldwide rights to the Cox-2 inhibitor cimicoxib.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Palau Pharma gives Affectis rights to Cox-2 inhibitor
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice